Market Intelligence, Clinical Progress, and High-Purity Reagents for Next-Generation NK Cell Checkpoint Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD94/KLRD1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD94/KLRD1 & NKG2A Heterodimer Recombinant Protein HEK293 expressed, Native Glycosylation, High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View CD94 Products |
| Gene Delivery | CD94/KLRD1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and surface expression validation. |
View CD94 Products |
| Benchmark Ab | Anti-CD94 Recombinant Antibody (Benchmark Sequence) Recombinant positive control for binding and flow cytometry assays. |
View CD94 Products |
| Validator | CD94/KLRD1 siRNA Set For target knockdown verification in primary NK cells or cell lines. |
View CD94 Products |
| Related Target A | NKG2A (KLRC1) The primary inhibitory partner forming heterodimers with CD94 to mediate HLA-E binding. |
View NKG2A Products |
| Related Target B | HLA-E The non-classical MHC class I ligand that interacts directly with the CD94/NKG2 complex. |
View HLA-E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Obligate Heterodimerization (CD94/NKG2A) | Co-expressed CD94/NKG2A heterodimer proteins with verified 1:1 stoichiometry and high purity (>95%) |
| Selectivity Screening (NKG2A vs. NKG2C) | Counter-screening panel featuring recombinant CD94/NKG2C activating complexes |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
| False Positives | Sequence-verified siRNA sets included for target-specific knockdown validation |
Live CD94/KLRD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD94/KLRD1 and NKG2A pathway therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific/multispecific engagers and combination therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the blockade of the HLA-E/CD94-NKG2A axis to unleash both NK cell and CD8+ T cell anti-tumor immunity in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | AstraZeneca, Innate Pharma | Head and Neck Cancer, Colorectal Cancer | Functional blocking assays (Need high-purity CD94/NKG2A heterodimers) |
| Bispecific/Multispecific | Leading Biotechs | Solid Tumors, Hematological Malignancies | Simultaneous binding kinetics (Need stable HLA-E and CD94/NKG2 heterodimers) |
| Cell Therapy (NK/CAR-NK) | Clinical Stage Biotechs | Refractory Solid Tumors | Surface knockout verification (Need high-efficiency Lentivirus and siRNA) |